Provides genetic and genomic diagnostic tests and interpretation services to clinicians, hospitals, and biopharma companies.
10-K for FY2025, filed Feb 23, 2026At GeneDx, our mission is to empower everyone to live their healthiest life through genomics. GeneDx combines clinical expertise, advanced…View ↗
The genome is composed of 3 billion “letters”, or base pairs, of DNA. The exome is a portion of the genome that encodes proteins, which are…View ↗
We also generate revenue from collaboration service agreements with biopharma companies and other third parties, pursuant to which we…View ↗
In addition, with the acquisition of Fabric Genomics, we generate revenues through software and interpretation services related to rare…View ↗
Most revenue comes from diagnostic tests: insurers, patients and institutions pay for a test when its results are delivered; institutions pay contracted rates. Collaboration agreements can also include nonrefundable and milestone payments.
10-K for FY2025, filed Feb 23, 2026The Company’s diagnostic test revenue contracts typically consist of a single performance obligation to deliver diagnostic testing services…View ↗
Diagnostic test revenues consist primarily of services reimbursed by third-party insurance payors. Third-party insurance payors include…View ↗
For institutional clients, the customer is the institution. The Company determines the transaction price associated with services rendered…View ↗
We also generate revenue from collaboration service agreements with biopharma companies and other third parties, pursuant to which we…View ↗
10-K for FY2025, filed Feb 23, 2026
FY2025 revenue by product or service ↗$427.5M
10-K for FY2025, filed Feb 23, 2026
$427.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Patients with third-party insurance
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
81%
FY2022: 74%
|
Patients with third-party insurance, FY2025
$345.2M Sources
|
Sold outright |
|
Institutional customers
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
16%
FY2022: 20%
|
Institutional customers, FY2025
$70.1M Sources
|
Sold outright |
|
Self-pay patients
Sold outright
|
0.3%
FY2022: 3.2%
|
Self-pay patients, FY2025
$1.4M Sources
|
Sold outright |
|
Other revenue
|
2.5%
FY2022: 3.1%
|
Other revenue, FY2025
$10.9M Sources
|
GeneDx sells diagnostic tests through its direct sales team and laboratory distribution partners; buyers include healthcare professionals ordering for patients and institutions such as hospitals, clinics, state governments and reference labs. Fabric also serves clinical laboratories and research institutions with software and interpretation services.
10-K for FY2025, filed Feb 23, 2026The principal focus of our commercial operations is to offer our diagnostic tests through both our direct sales force and laboratory…View ↗
The majority of our revenue is derived from genetic and genomic diagnostic testing services for three groups of customers: healthcare…View ↗
In addition, with the acquisition of Fabric Genomics, we generate revenues through software and interpretation services related to rare…View ↗
Not on paper. It lost $21M in FY2025, but brought in more cash than it spent: $14.3M of free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$12.3MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
Metric Full Year 2026 Previous Guidance Full Year 2026 Updated Guidance Fourth Quarter 2026 Guidance Revenue $475 to $490 million $475 to…View ↗
Growing. Revenue grew 2.0x in 4 years, from $212.2M in FY2021 to $427.5M in FY2025, about 19% a year.
Fabric software and interpretation
The older report described exome and genome interpretation and Centrellis platform services; the latest adds Fabric software and interpretation for rare disease, hereditary risk and cancer testing.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Feb 23, 2026Our primary growth engine in the short term will be expanding our current market-leading exome sequencing capabilities in the Neonatal…View ↗
Broader pediatric testing focus
The older report emphasized NICUs and pediatric developmental disorders; the latest also targets general pediatricians, other pediatric specialists and late-stage prenatal testing.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Feb 23, 2026Our primary growth engine in the short term will be expanding our current market-leading exome sequencing capabilities in the Neonatal…View ↗
Competes with Illumina, Baylor Genetics, Tempus, Ambry Genetics, Variantyx, and Rady Children’s Hospital
10-K for FY2025, filed Feb 23, 2026Our competitors include companies that offer molecular genetic testing and consulting services, including specialty and reference…View ↗
Loading...